Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Correction to: Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa.
GOVENDER, I; Karat, AS; Olivier, S; BAISLEY, K; Beckwith, P; Dayi, N; Dreyer, J; Gareta, D; Gunda, R; Kielmann, K; Koole, O; Mhlongo, N; Modise, T; Moodley, S; Mpofana, X; Ndung'u, T; Pillay, D; Siedner, MJ; Smit, T; Surujdeen, A; Wong, EB; GRANT, AD;
2022
CLINICAL INFECTIOUS DISEASES, (2022).75 2 10.1093/cid/ciac244.
National tuberculosis spending efficiency and its associated factors in 121 low-income and middle-income countries, 2010-19: a data envelopment and stochastic frontier analysis.
Abou Jaoude, GJ; Garcia Baena, I; Nguhiu, P; Siroka, A; Palmer, T; Goscé, L; ALLEL, K; Sinanovic, E; Skordis, J; Haghparast-Bidgoli, H;
2022
The Lancet Global Health, (2022).10 5 10.1016/S2214-109X(22)00085-7.
Updating age-specific contact structures to match evolving demography in a dynamic mathematical model of tuberculosis vaccination.
WEERASURIYA, CK; Harris, RC; MCQUAID, CF; Gomez, GB; WHITE, RG;
2022
PLoS Computational Biology, (2022).18 4 10.1371/journal.pcbi.1010002.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study.
Clark, R; Mukandavire, C; Portnoy, A; WEERASURIYA, C; Deol, A; Scarponi, D; Iskauskas, A; Bakker, R; Quaife, M; Malhotra, S; Gebreselassie, N; Zignol, M; Hutubessy, RC W; Giersing, B; JIT, M; Harris, R; Menzies, N; WHITE, R;
2022
medRxiv (2022). 10.1101/2022.04.16.22273762.
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.
Antimycobacterial Susceptibility Testing Group,;
2022
European Respiratory Journal, (2022).59 4 10.1183/13993003.00166-2022.
Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?.
DOCKRELL, HM; McShane, H;
2022
EBioMedicine, (2022).79, 10.1016/j.ebiom.2022.103993.
Cost-effectiveness of shortened regimens for DR-TB.
SWEENEY, S;
2022
(2022).
Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year's review.
Mujuni, D; Kasemire, DL; Ibanda, I; Kabugo, J; Nsawotebba, A; PHELAN, JE; Majwala, RK; Tugumisirize, D; Nyombi, A; Orena, B; Turyahabwe, I; Byabajungu, H; Nadunga, D; Musisi, K; Joloba, ML; Ssengooba, W;
2022
BMC INFECTIOUS DISEASES, (2022).22 1 10.1186/s12879-022-07339-w.
Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients.
Mbandi, SK; PAINTER, H; Penn-Nicholson, A; Toefy, A; Erasmus, M; Hanekom, WA; Scriba, TJ; Lai, RP J; Marais, S; Fletcher, HA; Meintjes, G; Wilkinson, RJ; Cotton, MF; Pahwa, S; Cameron, MJ; Nemes, E;
2022
European Journal of Immunology, (2022).52 7 10.1002/eji.202249815.
Comparing the performance of QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold in-tube among highly TB exposed gold miners in South Africa.
Ntshiqa, T; Chihota, V; Mansukhani, R; Nhlangulela, L; Velen, K; Charalambous, S; Maenetje, P; Hawn, TR; Wallis, R; GRANT, AD; Fielding, K; Churchyard, G;
2022
Gates Open Research, (2022).5, 10.12688/gatesopenres.13191.2.